产品介绍：
产品说明
生化/生理作用
Tivozanib (KRN951) is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). Tivozanib is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.
基本信息
| 经验(实验)分子式 | C22H19ClN4O5 |
| 分子量 | 454.86 |
| MDL编号 | MFCD15146788 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | white to beige |
| 溶解性 | DMSO: 2 mg/mL, clear |
| 储存温度 | 2-8℃ |
| SMILES string | O=C(NC1=C(Cl)C=C(C=C1)OC2=C3C=C(C(OC)=CC3=NC=C2)OC)NC4=NOC(C)=C4 |
安全信息
| 象形图 |  |
| 警示用语： | Warning |
| 危险声明 | H302 |
| 预防措施声明 | P264 - P270 - P301 + P312 - P501 |
| 危险分类 | Acute Tox. 4 Oral |
| 储存分类代码 | 11 - Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
